Table 1 Comparison of baseline characteristics between patients receiving NART and PORT in the setting of NAC in the whole cohort and matched cohort.
| Â | Whole Cohort | Matched Cohort | ||||
|---|---|---|---|---|---|---|
NART | PORT | P | NART | PORT | P | |
Age stage | Â | Â | 0.885 | Â | Â | 0.603 |
 ≤ 50 | 190 (49.2%) | 6902 (48.8%) |  | 184 (49.3%) | 726 (50.8%) |  |
 > 50 | 196 (50.8%) | 7227 (51.2%) |  | 189 (50.7%) | 702 (49.2%) |  |
Race | Â | Â | 0.159 | Â | Â | 0.291 |
 White | 275 (71.2%) | 10,147 (71.8%) |  | 266 (71.3%) | 1058 (74.1%) |  |
 Black | 77 (19.9%) | 2410 (17.1%) |  | 75 (20.1%) | 238 (16.7%) |  |
 Others* | 34 (8.8%) | 1572 (11.1%) |  | 32 (8.6%) | 132 (9.2%) |  |
Histologic grade | Â | Â | 0.875 | Â | Â | 0.602 |
 I | 13 (3.4%) | 548 (3.9%) |  | 13 (3.5%) | 62 (4.3%) |  |
 II | 127 (32.9%) | 4606 (32.6%) |  | 122 (32.7%) | 437 (30.6%) |  |
 III | 246 (63.7%) | 8975 (63.5%) |  | 238 (63.8%) | 929 (65.1%) |  |
AJCC stage |  |  |  < 0.001 |  |  | 0.796 |
 I | 32 (8.3%) | 1068 (7.6%) |  | 32 (8.6%) | 91 (6.4%) |  |
 IIA | 73 (18.9%) | 3468 (24.5%) |  | 72 (19.3%) | 277 (19.4%) |  |
 IIB | 93 (24.1%) | 3900 (27.6%) |  | 92 (24.7%) | 371 (26.0%) |  |
 IIIA | 79 (20.5%) | 2925 (20.7%) |  | 78 (20.9%) | 307(21.5%) |  |
 IIIB | 69 (17.9%) | 1583 (11.2%) |  | 63 (16.9%) | 241 (16.9%) |  |
 IIIC | 40 (10.4%) | 1185 (8.4%) |  | 36 (9.7%) | 141 (9.9%) |  |
T |  |  |  < 0.001 |  |  | 0.224 |
 T1 | 59 (15.3%) | 2471 (17.5%) |  | 59 (15.8%) | 193 (13.5%) |  |
 T2 | 163 (42.2%) | 6921 (49.0%) |  | 161 (43.2%) | 614 (43.0%) |  |
 T3 | 73 (18.9%) | 2829 (20.0%) |  | 72 (19.3%) | 330 (23.1%) |  |
 T4a–c | 57 (14.8%) | 1098 (7.8%) |  | 50 (13.4%) | 152 (10.6%) |  |
 T4d | 34 (8.8%) | 810 (5.7%) |  | 31 (8.3%) | 139 (9.7%) |  |
N | Â | Â | 0.350 | Â | Â | 0.592 |
 N0 | 125 (32.4%) | 4351 (30.8%) |  | 121 (32.4%) | 423 (29.6%) |  |
 N1 | 165 (42.7%) | 6587 (46.6%) |  | 160 (42.9%) | 665 (46.6%) |  |
 N2 | 56 (14.5%) | 2006 (14.2%) |  | 56 (15.0%) | 199 (13.9%) |  |
 N3 | 40 (10.4%) | 1185 (8.4%) |  | 36 (9.7%) | 141 (9.9%) |  |
Breast surgery |  |  |  < 0.001 |  |  | 0.896 |
 BCS | 123 (31.9%) | 6105 (43.2%) |  | 123 (33.0%) | 476 (33.3%) |  |
 Mastectomy | 263 (68.1%) | 8024 (56.8%) |  | 250 (67.0%) | 952 (66.7%) |  |
Axillary surgery | Â | Â | 0.005 | Â | Â | 0.882 |
 No LN removed | 36 (9.3%) | 776 (5.5%) |  | 25 (6.7%) | 89 (6.2%) |  |
 Biopsy | 191 (49.5%) | 7075 (50.1%) |  | 190 (50.9%) | 716 (50.1%) |  |
 Dissection | 159 (41.2%) | 6278 (44.4%) |  | 158 (42.4%) | 623 (43.6%) |  |
ER | Â | Â | 0.023 | Â | Â | 0.282 |
 Negative | 181 (46.9%) | 5808 (41.1%) |  | 173 (46.4%) | 618 (43.3%) |  |
 Positive | 205 (53.1%) | 8321 (58.9%) |  | 200 (53.6%) | 810 (56.7%) |  |
PR | Â | Â | 0.016 | Â | Â | 0.169 |
 Negative | 229 (59.3%) | 7506 (53.1%) |  | 217 (58.2%) | 774 (54.2%) |  |
 Positive | 157 (40.7%) | 6623 (46.9%) |  | 156 (41.8%) | 654 (45.8%) |  |
HER2 (since 2010) | Â | Â | 0.316 | Â | Â | 0.707 |
 Negative | 171 (69.2%) | 6949 (66.2%) |  | 170 (69.1%) | 665 (67.9%) |  |
 Positive | 76 (30.8%) | 3551 (33.8%) |  | 76 (30.9%) | 315 (32.1%) |  |
